Cargando…
Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745040/ https://www.ncbi.nlm.nih.gov/pubmed/35011801 http://dx.doi.org/10.3390/jcm11010064 |
_version_ | 1784630248896200704 |
---|---|
author | Berar-Yanay, Noa Freiman, Sarit Shapira, Maʹanit Saffoury, Amer Elemy, Ameer Hamze, Munir Elhaj, Mohamad Zaher, Maha Matanis, Loai Armaly, Zaher Anis |
author_facet | Berar-Yanay, Noa Freiman, Sarit Shapira, Maʹanit Saffoury, Amer Elemy, Ameer Hamze, Munir Elhaj, Mohamad Zaher, Maha Matanis, Loai Armaly, Zaher Anis |
author_sort | Berar-Yanay, Noa |
collection | PubMed |
description | Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (p < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (p < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. In conclusion: the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity. |
format | Online Article Text |
id | pubmed-8745040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87450402022-01-11 Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients Berar-Yanay, Noa Freiman, Sarit Shapira, Maʹanit Saffoury, Amer Elemy, Ameer Hamze, Munir Elhaj, Mohamad Zaher, Maha Matanis, Loai Armaly, Zaher Anis J Clin Med Article Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (p < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (p < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. In conclusion: the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity. MDPI 2021-12-23 /pmc/articles/PMC8745040/ /pubmed/35011801 http://dx.doi.org/10.3390/jcm11010064 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Berar-Yanay, Noa Freiman, Sarit Shapira, Maʹanit Saffoury, Amer Elemy, Ameer Hamze, Munir Elhaj, Mohamad Zaher, Maha Matanis, Loai Armaly, Zaher Anis Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
title | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
title_full | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
title_fullStr | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
title_full_unstemmed | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
title_short | Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients |
title_sort | waning humoral response 3 to 6 months after vaccination with the sars-cov-2 bnt162b2 mrna vaccine in dialysis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745040/ https://www.ncbi.nlm.nih.gov/pubmed/35011801 http://dx.doi.org/10.3390/jcm11010064 |
work_keys_str_mv | AT beraryanaynoa waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT freimansarit waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT shapiramaʹanit waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT saffouryamer waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT elemyameer waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT hamzemunir waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT elhajmohamad waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT zahermaha waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT matanisloai waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients AT armalyzaheranis waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients |